Abstract
Liquid biopsy specialist Cynvenio Bio-systems and Color, a cancer risk screening company, announced a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 in combination with Cynvenio’s ClearID Breast Cancer test, which interrogates 27 genes for somatic mutations in breast cancer.
“Even well into therapy, too many patients do not seek BRCA testing because of concerns over cost or other reasons, which is unfortunate because BRCA status is important for evaluating treatment strategies,” said André de Fusco, Cynvenio’s CEO. “With this new combined offering, we have demolished the cost barrier and integrated the biology, which will expand the availability of BRCA and hereditary cancer testing to more people who could benefit from it.”
Mutations in the BRCA1 and BRCA2 genes are known risk factors for breast cancer. In addition to screening for the BRCA1 and BRCA2 genes associated with breast cancer risk, the Color Test also includes other genes associated with increased risk for the most common hereditary cancers, including colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. Once screening has been completed, Color makes available board-certified genetic counseling to both patients and clinicians.
Cynvenio’s ClearID Breast Cancer test analyzes DNA from multiple sources in the bloodstream, including circulating tumor cells (CTC), plasma or cell-free DNA (cfDNA), and germline DNA. The ClearID test was designed for patients undergoing treatment for advanced breast cancer and those requiring follow-up testing at regular intervals after completion of therapy.